Second Quarter 2024 Updates, Including Double-Digit Revenue Growth

Submitted by admin-cpharma on Wed, 08/14/2024 - 17:24

We were pleased to report that Cumberland delivered a strong financial performance for the second quarter.

First Quarter 2024 Updates, Including a Special Report for Our Caldolor Product

Submitted by admin-cpharma on Wed, 05/15/2024 - 15:49

Overall, the first quarter proved to be a productive start to the year.

2023 Highlights, Including Expanded FDA Approval And New Study Publications

Submitted by admin-cpharma on Wed, 03/13/2024 - 14:55

In many ways 2023 was a building year for Cumberland, as we continued to integrate our newest products, while also delivering several significant achievements. 

Third Quarter 2023 Updates, 
Including Our New Mission Statement

Submitted by admin-cpharma on Tue, 11/14/2023 - 14:45

During the third quarter, we refined our mission statement to better capture the spirit of what we endeavor to do each day here at Cumberland Pharmaceuticals. It now reads as follows:

Second Quarter 2023 Updates, Including Expanded FDA Approval for Caldolor and Publication of Newborn Clinical Study Results

Submitted by admin-cpharma on Mon, 08/14/2023 - 13:53

In the second quarter of 2023, we advanced our business, as the operating environment continued to slowly improve from the post-pandemic challenges. Our team has been working diligently to maximize the potential of our commercial brands, progress our pipeline and pursue select acquisitions. 

First Quarter 2023 Updates, Including NOPAIN Act and FDA Fee Waiver

Submitted by admin-cpharma on Tue, 05/16/2023 - 14:27

We have continued to successfully manage our business despite the challenges in our operating environment. Our team has remained dedicated to delivering high-quality medicines for our patients, while also developing new medicines for the future.